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ABSTRACT
Aromatic amino and nitro compounds are potent
carcinogens found in the environment that exert
their toxic effects by reacting with DNA following
metabolic activation. One important adduct is
N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-
AAF), which has been extensively used in studies
of the mechanisms of DNA repair and mutagenesis.
Despite the importance of dG-AAF adducts in DNA,
an efficient method for its incorporation into DNA
using solid-phase synthesis is still missing. We report
the development of a modified ‘ultra-mild’ DNA syn-
thesis protocol that allows the incorporation of dG-
AAF into oligonucleotides of any length accessible
by solid-phase DNA synthesis with high efficiency
and independent of sequence context. Key to this
endeavor was the development of improved depro-
tection conditions (10% diisopropylamine in
methanol supplemented with 0.25 M of b-mercapto-
ethanol) designed to remove protecting groups of
commercially available ‘ultra-mild’ phosphoramidite
building blocks without compromising the integrity
of the exquisitely base-labile acetyl group at N8 of
dG-AAF. We demonstrate the suitability of these
oligonucleotides in the nucleotide excision repair
reaction. Our synthetic approach should facilitate
comprehensive studies of the mechanisms of repair
and mutagenesis induced by dG-AAF adducts in DNA
and should be of general use for the incorporation of
base-labile functionalities into DNA.
INTRODUCTION
The preparation of defined single site-specific DNA
damages is often the limiting step in understanding the repair
characteristics or the mutagenic properties of a given lesion.
The toxicological studies of potent aromatic nitro or amino
carcinogens present in cooked food, tobacco smoke or diesel
exhaust (1–3) illustrate this point; they are typically performed
by exposing cells or oligonucleotides to the compound of
interest, usually in an activated form (4–9). These approaches,
however, lead invariably to inextricable mixtures of DNA
lesions containing multiple and heterogeneous adducts at
random sites, and are of limited use for studies concerning
the molecular mechanisms underlying mutagenesis or
DNA repair. For instance, N-acetoxy-2-acetylaminofluorene
(N-AAAF) (1), a compound commonly used as reference
in mutagenesis studies, is known to react predominantly
with 20-deoxyguanosine (dG) (2) residues in DNA to produce
at least three different adducts (2,10–12) (Figure 1): N-
(deoxyguanosin-N2-yl)-2-acetylaminofluorene (dG-N2-AAF)
(3), N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF)
(4) and N-(deoxyguanosin-8-yl)-2-aminofluorene (dG-AF)
(5). To generate defined single AAF adducts, the commonly
used strategy consists in the treatment of a short oligonuc-
leotide containing a unique reactive dG residue with N-AAAF
(6,13–16). Although this approach is limited in terms of
accessible sequences and yields to heterogeneous mixtures
of adducts (11,12,17), it has been used in conjunction with
extensive high-performance liquid chromatography (HPLC)
purification to prepare defined single dG-AAF adducts in
oligonucleotides containing up to three guanine residues
(18–21). Biochemical studies using these well-defined dam-
aged oligonucleotides have allowed invaluable insights into
the impact of these lesions on DNA structure (22–24), rep-
lication (24–26), mutagenesis (14,15,20,27–29) and repair
(6,19,30,31). Despite these advances, the generation of
AAF-containing oligonucleotides by solid-phase DNA syn-
thesis would greatly facilitate further biological investiga-
tions. Early studies along those lines quickly revealed that
the ammonia deprotection step required after solid-phase syn-
thesis compromised the integrity of the N8 acetyl group of the
dG-AAF adduct (32). In 1993, Zhou and Romano reported the
successful incorporation of an Fmoc-protected dG-AAF
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phosphoramidite in a 12mer oligonucleotide (33,34). The use
of Fmoc as a protecting group for the exocyclic amines of all
the bases, made it possible to perform a mildly basic depro-
tection step, devised to preserve the N8 acetyl group of
dG-AAF (33). Unfortunately, the fact that Fmoc-protected
phosphoramidites are not commercially available and that
their preparation is cumbersome has prevented this method
from finding widespread use. The post-synthetic modification
strategy has thus so far remained the standard procedure for
the preparation of AAF-modified oligonucleotides (21,29,35).
In the context of our studies on damage recognition and cata-
lysis in nucleotide excision repair (NER) (36–38), we wished
to develop a general approach for the synthesis of oligonuc-
leotides containing defined, site-specific dG-AAF adducts.
Our goal required two main issues to be resolved: (i) the
efficient preparation of C8-amine and acetylamine adducts
of dG and (ii) the development of a general and straightfor-
ward solid-phase DNA synthesis protocol for the incorpora-
tion of dG-AAF residues that does not compromise the
integrity of the base-labile N8 acetyl group. We (39) and
some others (40,41) have previously described a solution to
the first issue by preparing arylamine adducts at the C8 posi-
tion of dG using a Buchwald–Hartwig coupling reaction
between various aromatic amines and a protected 8-bromo-
20-deoxyguanosine. We have further established that these
adducts can be specifically acetylated at the N8 position
and can be suitably protected for DNA synthesis (39).
Here, we describe a new protocol for the site-specific incorp-
oration of exquisitely base-labile residues into DNA and its
application for the synthesis of dG-AAF-containing oligonuc-
leotides, ranging from 9mer to 120mer. Our approach allows
the generation of dG-AAF and dG-AF modified oligonuc-
leotides of any length and sequence. As an example of an
application, these oligonucleotides are incorporated into plas-
mids and the repair efficiencies of dG-AAF and dG-AF resi-
dues were compared. The approach described here should be
generally applicable for the preparation of oligonucleotides
containing base-labile modifications.
Figure 1. Commonly formed adducts of N-acetoxy-2-acetylaminofluorene with 20-deoxyguanosine. N-AAAF can react with dG residues in DNA to form at least
three different adducts: 3-(deoxyguanosin-N2-yl)-2-acetylaminofluorene (3) (dG-N2-AAF); N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (4) (dG-AAF); and
N-(deoxyguanosin-8-yl)-2-aminofluorene (5) (dG-AF). dG, dG-N2-AAF and dG-AF are believed to have the base mainly in the syn conformation, while the
anti conformation is favored in dG-AAF.
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MATERIALS AND METHODS
Reagents and equipment
Chemicals and solvents were purchased from Fluka-Sigma-
Aldrich. Reagents for DNA synthesis were purchased from
Applied Biosystem, except for 5-ethylthio-1H-tetrazole,
which was from Sigma and was recrystallized from dry tolu-
ene before use. The ‘ultra-mild’ phosphoramidites were avail-
able from Glen Research and the 1000 s ‘Q-columns’ from
Biosearch Technologies. DNA syntheses were performed on a
PerSeptive Biosystems Expedite 8909. HPLC analysis and
purifications were performed on a JASCO system equipped
with a BGB Analytik column: Nucleosil 100 s, C18, 5 mm,
250 · 4.0 mm2. The C18-SepPak cartridges were from
Micropore. Snake venom phosphodiesterase I (SVPD) was
from Worthington Biochemical; calf intestine phosphatase,
T4 PNK, T4 DNA polymerase, T4 DNA ligase from New
England Biolabs. The sequenase enzyme (T7 DNA poly-
merase) was purchased from USB and [a-32P]dCTP from
Amersham.
NMR spectra were recorded on a Bruker ARX-300 MHz,
the HR-MALDI on an Ionspec FT MS Ultima. The 9mer and
24mer were analyzed by nano-ESI on a Micromass quadrupole
time-of-flight (Q-TOF) mass spectrometer in negative mode;
the 60mer, 90mer and 120mer were analyzed by LC-ESI-MS
in negative mode on a Q-TOF-Ultima coupled to Cap-LC (see
Supplementary Material). The mass deconvolution was real-
ized with the MaxEnt1 software.
Synthesis of the iPrPac-dG-AAF building block
(50-O-Dimethoxytrityl)-N-[(N2-isopropylphenoxyacetyl)-
deoxyguanosin-8-yl]-2-acetylaminofluorene. To N-[(N2-iso-
propylphenoxyacetyl)-deoxyguanosin-8-yl]-2-acetylamino-
fluorene (6) (39) (671 mg, 1.0 mmol) dissolved in pyridine
(5 ml), 4,4-dimethoxytrityl chloride (514 mg, 1.5 mmol) was
added. The reaction mixture was stirred for 2 h at room
temperature, concentrated and purified by chromatography
on silica gel (CH2Cl2/MeOH 40:1) to provide 741 mg
(0.77 mmol, 76%) of a slightly yellow powder.
Rf = 0.50 (CH2Cl2/MeOH 10:1).
1H NMR [DMSO-d6, d (p.p.m.)]: 11.76 (s, 1H, N1-H), 11.30
(s, 1H, N2-H), 7.84–7.95 (m, 2H, AF-H2), 7.44–7.78 (m, 3H,
AF-H3), 7.25–7.41 (m, 4H, AF-H2 +DMTr-H2), 7.05–7.21 (m,
9H, Pac-H2 + DMTr-H7), 6.89 (d, J = 8.7, 2H, Pac-H2), 6.56–
6.73 (m, 4H, DMTr-H4), 6.32 (dd, J = 6.9, 7.2, 1H, C10-H),
5.19 (d, J = 5.3, 1H, C30-OH), 4.79 (m, 2H, Pac-CH2), 4.61 (m,
1H, C3
0-H), 4.07 (m, 1H, C40-H), 3.86 (m, 2H, AF-C9-H2), 3.66
(s, 3H, OMe), 3.64 (s, 3H, OMe), 3.39 (m, 1H, C5
0-H), 3.16
(m, 1H, C5
0-H), 2.99 (m, 1H, C20-H), 2.85 (sept, J = 6.9, 1H,
iPr-H), 2.30 (m, 1H, C2
0-H), 2.11 (br s, 3H, N-Ac), 1.18 (s, 3H,
iPr-CH3), 1.16 (s, 3H, iPr-CH3).
13C-NMR [DMSO-d6, d (p.p.m.)]: 170.5, 157.8, 157.7,
155.6, 154.2, 147.3, 146.4, 144.7, 143.9, 143.2, 141.4,
140.0, 135.5, 129.6, 129.5, 127.7, 127.2, 127.1, 126.9,
126.7, 126.2, 124.9, 123.7, 120.3, 120.1, 119.1, 114.4,
112.6, 112.5, 86.8, 85.1, 83.7, 78.9, 70.1, 66.5, 64.9, 54.8,
54.7, 37.5, 36.3, 32.4, 30.5, 23.9, 22.5.
HR-MALDI (m/z): calcd for C57H54N6O9Na+ 989.3845;
found, 989.3831.
[30-O-(20-Cyanoethoxydiisopropylaminophosphino)]-(50-O-
dimethoxytrityl)-N-[(N2-isopropylphenoxyacetyl)-deoxy-
guanosin-8-yl]-2-acetylaminofluorene (7). To (50-O-dimeth-
oxytrityl)-N-[(N2-isopropylphenoxyacetyl)-deoxyguanosin-8-
yl]-2-acetylaminofluorene (679 mg, 0.7 mmol) in CH2Cl2
(5 ml) N-ethyldiisopropylamine (480 ml, 2.8 mmol) and
2-cyanoethoxydiisopropylchloro-phosphoramidite (313 ml,
1.4 mmol) were added. The reaction mixture was stirred for
2 h at room temperature, concentrated to dryness and redis-
solved in the miminal amount of CH2Cl2. 40 ml of hexane was
then added under smooth stirring and the product was further
precipitated for 2 h at 20C. The clear supernatant was then
removed and the residue was purified by chromatography
on silica gel (CH2Cl2/MeOH 40:1) to provide 710 mg
(0.61 mmol, 86%) of a slightly yellow powder.
Rf = 0.54 (CH2Cl2/MeOH 10:1).
1H NMR [DMSO-d6, d (p.p.m.)]: 11.80 (s, 1H, N1-H), 10.97
(s, 1H, N2-H), 7.86–7.94 (m, 2H, AF-H2), 7.50–7.81 (m, 3H,
AF-H3), 7.26–7.41 (m, 4H, AF-H2 + DMTr-H2), 7.09–7.19
(m, 9H, Pac-H2 + DMTr-H7), 6.88–6.93 (m, 2H, Pac-H2),
6.60–6.72 (m, 4H, DMTr-H4), 6.34 (m, 1H, C1
0-H), 4.65–
4.88 (m, 3H, Pac-CH2 + C30-H), 4.17 (m, 1H, C40-H), 3.81–
3.95 (m, 2H, AF-C9-H2), 3.61–3.69 (m, 7H, 2xOMe + C50-H2),
3.37–3.58 (m, 4H, O-CH2-CH2-CN), 3.13–3.27 (m, 2H,
C5
0-H2 + C20-H), 2.84 (sept, J = 6.9, 1H, Pac-iPr-H),
2.59–2.75 (m, 2H, N-iPr2-H2), 2.39 (m, 1H, C2
0-H), 2.10
(br s, 3H, N-Ac), 0.94–1.29 (m, 18H, Pac-iPr-(CH3)2 + N-
iPr2-(CH3)4).
13C-NMR [DMSO-d6, d (p.p.m.)]: 157.8, 157.7, 155.6,
144.7, 144.6, 144.5, 143.2, 141.3, 141.1, 140.0, 138.9,
135.4, 135.4, 129.6, 129.5, 127.7, 127.6, 127.6, 127.6,
127.5, 127.3, 127.1, 127.0, 127.0, 126.7, 126.3, 126.2,
125.0, 120.1, 118.8, 118.6, 118.5, 118.0, 114.4, 114.3,
112.7, 112.6, 107.6, 85.3, 85.2, 60.3, 58.1, 58.0, 57.2, 57.1,
56.4, 54.8, 54.8, 54.7, 46.1, 44.4, 44.4, 42.6, 42.5, 36.3, 32.5,
32.4, 24.2, 24.1, 24.0, 24.0, 23.9, 23.9, 23.8, 22.5, 22.5, 22.4,
20.9, 19.7, 19.6, 19.5, 19.5, 19.3, 19.2, 19.1, 19.1, 19.0, 18.7.
31P-NMR f1Hg NMR [DMSO-d6, d (p.p.m.)]: 148.4 (s),
148.0 (s).
HR-MALDI (m/z): calcd for C66H71N8O10PNa+
1189.4923; found, 1189.4907.
Modified ‘ultra-mild’ solid-phase DNA synthesis and
deprotection conditions
The sequences prepared, with the exception of the 9mer, were
designed to be complementary to the (+) strand of pBluescript
II SK and are as follows: 9mer, d(CGATG*CAGT); 24mer,
d(GTATCGATAAG*CTTGATATCGAAT); 60mer, d(CCC-
CCCTCGAGGTCGACGGTATCGATAAG*CTTGATATC-
GAATTCCTGCAGCCCGGGGGAT); 90mer, d(CAAAAGC-
TGGGTACCGGGCCCCCCCTCGAGGTCGACGGTATCG-
ATAAG*CTTGATATCGAATTCCTGCAGCCCGGGGGA-
TCCACTAGTTCT); and 120mer, d(CGTAATACGACTC-
ACTATAGGGCGAATTGGGTACCGGGCCCCCCCTCG-
AGGTCGACGGTATCGATAAG*CTTGATATCGAATTC-
CTGCAGCCCGGGGGATCCACTAGTTCTAGAGCGGC-
CG); where G* denotes dG (unmodified), dG-AAF or dG-AF.
All DNA syntheses were performed on 1 mM scale, 1000 s
‘Q-columns’. The ‘ultra-mild’ phosphoramidites (T, Ac-dC,
Pac-dA and iPrPac-dG) were dissolved to 0.1 M in CH3CN.
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The iPrPac-dG-AAF phosphoramidite (7) was dissolved to
0.1 M in CH2Cl2 and its coupling time during the DNA syn-
thesis extended to 12 min. A 0.25 M solution of 5-(ethylthio)-
1H-tetrazole in CH3CN was used as an ‘activator’. A 0.5 M
solution of phenoxyacetyl anhydride [prepared according to a
published procedure (42)] in THF was used as ‘capping A’
solution with an extended capping time of 6 s and double
amount of reagent delivered on the solid support in compar-
ison with the standard 1 mM scale DNA synthesis protocol. A
3% (v/v) dichloroacetic acid solution in CH2Cl2 was used in
the deblocking step. The final 50-DMTr protective group was
retained for all the syntheses (‘DMTr-ON’ synthesis). After
completion of the synthesis, the solid support was dried
and treated overnight at 55C with a solution containing
10% (v/v) of diisopropylamine (iPr2NH) and 0.25 M of
b-mercaptoethanol in MeOH. The supernatant containing
the released oligonucleotide was decanted and concentrated,
taken up in 1 ml of 1 M triethylamoniumacetate (TEAA)
buffered at pH 7, passed through a 0.45 mm filter and purified
by HPLC.
HPLC purification
All HPLC elutions were performed at a flow rate of 1 ml/min,
with the following gradient: linear 5–20% B over 15 min,
linear 20–75% B until 30 min, isocratic 75% B until
35 min, linear 75–5% B until 36 min, isocratic 5% B until
40 min; buffer A, 0.1 M TEAA (pH 7); and buffer B, CH3CN.
The peak of the ‘DMTr-ON’ oligonucleotide, eluting between
20 and 22 min, was collected (see Supplementary Material),
concentrated and treated with an 80% acetic acid solution for
40 min at room temperature to remove the 50-DMTr group.
After concentration, the oligonucleotide was redissolved in
1 ml of 1 M TEAA buffered at pH 7 and repurified on
HPLC. The major peak—eluting between 15 and 17 min—
was collected, concentrated, redissolved in 0.1 M TEAA (pH 7),
desalted on a C18-SepPak cartridge and lyophilized. The
lyophilizate was redissolved in 300–400 ml of milli-Q water
to typically yield concentrations of 100–600 pmol/ml (mM).
With protocols optimized for the generation of highly
pure oligonucleotides, yields were as follows: 9-AAF,
57–103 nmol (6–10%); 24-AAF, 24–62 nmol (2.6%);
60-AAF, 28–57 nmol (3–6%); 90-AAF, 15 nmol (1.5%);
and 120-AAF, 0.2 nmol (0.02%). For the preparation of the
corresponding dG-AF adduct, the oligonucleotide containing
the dG-AAF modification was incubated for 3 h at 37C in a
1 M solution of NaOH containing 0.25 M of b-mercaptoeth-
anol, according to a published procedure (12). The solution
was then neutralized with 1 M HCl and directly desalted on a
C18-SepPak cartridge and lyophilized.
Enzymatic digestion analysis
The modified DNA (25 ml; between 2 and 10 nmol) was
incubated for 7 h at 37C with 20 ml of snake venom phos-
phodiesterase (2 U) in a buffered solution containing 20 mM
Tris–HCl, 10 mM MgCl2, 100 mM NaCl at pH 9 (5 ml of a pre-
made 10· buffer). The reaction mixture was then incubated for
15 min at 37C with 0.5 ml (5 U) of calf intestine phosphatase
and directly injected into the HPLC using the gradient
described above. For the digestion of oligonucleotide contain-
ing the dG-AF adduct, the addition of 1 mM of DTT to the
digestion buffer was necessary to avoid complete oxidation
and degradation of the dG-AF nucleoside (5) (32,43,44).
The resulting peaks were identified by co-injection with the
corresponding standards and eluted at the following time peri-
ods: dC (3.4 min), dG (5.5 min), T (6.3 min), dA (8.2 min),
dG-AAF (24.2 min), dG-AF (24.8 min) and iPrPac-dG-AAF
(30.8 min).
Primer extension and in vitro NER assay
An aliquot of 120 pmol of 24-AAF (or 24-AF) oligonucleotide
was 50-phosphorylated by incubation with 20 U of T4 PNK
enzyme and 2 mM of ATP for 2 h. After annealing with
30 pmol of single-stranded pBluescript II SK+, further incuba-
tion with dNTPs, T4 DNA polymerase and T4 DNA ligase
(45) yielded covalently closed circular DNA containing a
single AAF (or AF) adduct. The closed circular DNA was
purified by caesium chloride/ethidium bromide density gradi-
ent centrifugation, by consecutive butanol extractions to
remove the ethidium bromide and finally concentrated on a
Centricon YM-30 (Millipore). In addition to the published
purification procedure (45), the plasmid was repurified by
1% agarose gel electrophoresis to remove traces of the 24-
AAF (or 24-AF) oligonucleotides that remained associated
with the plasmid during CsCl purification. The band of the
closed circular plasmid was excised from the agarose gel and
purified with the QIAquick Gel Extraction Kit from Qiagen.
The dG-AAF and dG-AF containing plasmids were aliquoted
and stored at 80C. HeLa whole-cell extracts were prepared
as described (46), aliquoted and stored at 80C. The in vitro
NER assay was performed as described (45) and the
excised NER products detected after annealing with the fol-
lowing complementary 30-phosphorylated oligonucleotide:
d(GGGGGATATCAAGCTTATCGATACCGTCGACCTCG).
Subsequent fill-in reaction of [a-32P]dCTP was performed
in the presence of sequenase enzyme as described previously
(45). The reactions were analyzed on a 14% denaturing
polyacrylamide sequencing gel (migrating for 2 h at 50 W)
and exposed overnight to a BioMax MS (Kodak) film
at 80C.
RESULTS AND DISCUSSION
Development of an improved ‘ultra-mild’ deprotection
procedure
The exquisite base sensitivity of the acetyl group in dG-AAF
provides a challenge for the conditions used in the deprotec-
tion step following the solid-phase DNA synthesis. Previous
studies have revealed that this N8 acetyl group is readily
cleaved upon treatment with ammonia (32) or K2CO3/
MeOH under the standard deprotection conditions described
for ‘ultra-mild’ DNA synthesis (33,47). To date, the only
solution to this problem was provided by Zhou and Romano
(33), who used Fmoc as protecting group for the exocylic
amines of all the phosphoramidites and 1:9 piperidine/
MeOH or 1:1 diisopropylamine/MeOH as a mildly basic
deprotection solution. Since the Fmoc-protected building
blocks are not commerically available and are not trivial to
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synthesize, we sought to develop conditions that would cleave
the protecting groups of the commercial ultra-mild phosphor-
amidites (iPrPac-dG, Pac-dA and Ac-dC) but would retain the
acetyl group on dG-AAF. As a first step toward this goal, we
had previously reported that treatment of iPrPac protected dG-
AAF (6) with a 5% diisopropylamine (iPr2NH) solution in
methanol (12 h, room temperature), led to deprotection of
the N2-iPrPac group without detectable loss of the N8 acetyl
group (39). This suggested that deprotection of oligonuc-
leotides prepared with the commercial ultra-mild phosphor-
amidites could be achieved under conditions compatible with
the maintenance of the acetyl group of AAF. We, therefore,
assessed further the stability of the iPrPac protected dG-AAF
(6) under prolonged incubation with the various reagents
used in DNA synthesis, to determine whether additional
modifications were necessary. Preliminary tests showed that
iPrPac-dG-AAF (6) was stable toward the capping reagent
[phenoxyacetic anhydride was used rather than acetic anhyd-
ride to avoid transamidation reactions on the Pac/iPrPac
protected exocyclic amines (48)], the activator [5-(ethylthio)-
tetrazole was used rather than tetrazole to avoid precipitation
and for improved coupling yields] and the oxidizing solutions
were used during the DNA synthesis (data not shown). How-
ever, the modified nucleoside (6) underwent complete depur-
ination almost instantly upon incubation with the deblocking
solutions: 3–5% (v/v) trichloroacetic acid or dichloroacetic
acid (DCA) in CH2Cl2. Propensity similar to depurination
had also been described for Fmoc-dG-AAF on the mononuc-
leoside level (33). Further tests demonstrated, however,
that the use of 3% (v/v) DCA/CH2Cl2 did not lead to any
depurination of iPrPac-dG-AAF during solid-phase DNA
synthesis and this mixture was thus used in the deblocking
step.
The last issue to be addressed was the choice of a solid-
support. Initial experiments revealed that, whereas a solution
of 0.05 M K2CO3/MeOH readily released an oligonucleotide
from a solid support with a succinimid linker, a 5% iPr2NH
solution in methanol led only to a marginal recovery of the
expected oligonucleotide. Resorting to the more labile
hydroquinone-based ‘Q-support’ (49), however, adequately
addressed this issue. We then carried out a solid-phase syn-
thesis of a model 9mer oligonucleotide using all of these
modifications (summarized in Table 1). Following deprotec-
tion and purification of the oligonucleotide by using HPLC,
nano-ESI MS revealed that all the protective groups of the
bases and of the phosphate backbone had been released
(Table 2 and Supplementary Material), thus validating our
synthesis and deprotection conditions.
Preparation and analysis of dG-AAF and dG-AF
modified 9mer oligonucleotides
With the improved ultra-mild DNA synthesis and deprotection
protocol in hand, we assessed its usefulness to incorporate dG-
AAF residues into oligonucleotides. To be consistent with the
‘ultra-mild’ iPrPac protected dG, we had previously reported
the preparation of N2-iPrPac protected dG-AAF (6) (39).
50-Dimethoxytrityl protection of iPrPac-dG-AAF (6) and
subsequent 30-phosphitylation to (7) were performed accord-
ing to the standard procedures (Figure 2). The iPrPac-dG-AAF
phosphoramidite (7) was dissolved to 0.1 M in CH2Cl2, which
provided improved stability and coupling efficiency over acet-
onitrile. We prepared then a 9mer (9-AAF) containing a single
dG-AAF adduct using the conditions summarized in Table 1,
and purified the oligonucleotide by HPLC. The HPLC trace
revealed the homogeneity and the purity of the dG-AAF
modified oligonucleotide (Figure 3A). Treatment of 9-AAF
for 3 h at 37C in a 1 M NaOH solution containing 0.25 M of
b-mercaptoethanol (12) led to selective cleavage of the N8
acetyl and to the formation of corresponding dG-AF modified
9mer (9-AF). The 9-AAF and 9-AF oligomers eluted at two
distinct retention times on HPLC (Figure 3), confirming the
effective removal of the acetyl group from 9-AAF to yield the
less polar 9-AF (12), and proving that the purified 9-AAF was
really exempt of decomposition into the deacetylated 9-AF.
Nano-ESI analyses confirmed the identity and purity of the
9-AAF and 9-AF (Table 2 and Supplementary Material).
We performed an enzymatic digestion analysis of the
9-AAF and 9-AF oligonucleotides to further prove the pres-
ence of dG-AAF and dG-AF, respectively, and to rule out the
possibility that the additional acetyl group in 9-AAF was loc-
ated on a dC residue because of incomplete deprotection of an
acetyl-dC. The modified oligonucleotides were incubated with
a large excess of snake venom phosphodiesterase I at 37C for
7 h, since it was described that this enzyme is partially blocked
at the site of the dG-AAF lesion (50). Following incubation
with calf intestine phosphatase, the resulting nucleosides
were separated by HPLC and the different peaks assigned
by co-elution with the corresponding reference compounds
(Figure 3). These studies confirmed the unique presence of
dG-AAF in 9-AAF and of dG-AF in 9-AF, in addition to the
four normal nucleosides. This thus demonstrated that the addi-
tional acetyl group measured by nano-ESI in 9-AAF, was
Table 1. Modified ‘ultra-mild’ DNA synthesis
Modified ‘ultra-mild’ protocol
Solid support Hydroquinone based (‘Q-column’)
Phosphoramidites dT, Ac-dC, Pac-dA, iPrPac-dG (0.1 M in CH3CN)
Modification iPrPac-dG-AAF (0.1 M in CH2Cl2)
 Coupling time extended to 12 min
Activator 5-(Ethylthio)-1H-tetrazole (0.25 M in CH3CN)
Oxidizer I2 (0.1 M in THF/pyridine/H2O)
CappingA iPrPac anhydride (0.5 M in THF)
 Capping time extended to 6 s
 Delivered double volume of solution
Capping B 1-Methylimidazole (2 M in THF)
Deblock DCA (3%, v/v) in CH2Cl2
Deprotection iPr2NH (10%, v/v), 0.25 M b-mercaptoethanol in MeOH
 Overnight treatment at 55C
Table 2. MS analyses of the synthesized oligonucleotides
Oligonucleotide Calcd mass Measured
9-Unmod 2738.9 2739
9-AAF 2960.2 2960
9-AF 2918.1 2918
24-AAF 7612.2 7611
24-AF 7570.1 7569
60-AAF 18 674.4 18 672
90-AAF 27 928.4 27 927
120-AAF 37 262.4 37 262
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indeed located on the expected N8 position of the modified dG
adduct. Taken together, the analytical data fully validate the
modified ‘ultra-mild’ deprotection protocol for the preparation
of dG-AAF and dG-AF modified 9mer.
Optimization of the deprotection conditions and
preparation of 24-AAF, 24-AF, 60-AAF,
90-AAF and 120-AAF
When we applied the same protocol for the preparation of
longer oligonucleotides (24mer to 120mer) containing a single
dG-AAF modification, we obtained, to our surprise, HPLC
elution profiles presenting broader peaks, suggesting that a
heterogeneous mixture of oligonucleotides had been formed.
Indeed, MS analysis confirmed that we had purified a com-
bination of oligonucleotides containing up to four additional
acetyl groups. Since the Ac-dC residues are the only plausible
source of acetyl groups, it appeared that our deprotection
conditions were not strong enough to remove all the protecting
groups from these residues.
We decided thus to use harsher conditions and to treat the
oligonucleotides with a methanolic solution containing 10%
(v/v) iPr2NH and 0.25 M b-mercaptoethanol for 20 h at 55C.
b-Mercaptoethanol was added to avoid aerial oxidation of dG-
AAF arising during long incubation at higher temperatures
(43,44). Although preliminary stability tests at the nucleoside
level with iPrPac-dG-AAF (6) revealed some cleavage of the
N8 acetyl group of dG-AAF under these conditions, no decom-
position was observed at the oligonucleotide level. Using these
conditions, we could indeed prepare a 24mer, a 60mer, a
90mer and even a 120mer containing each a single dG-AAF
modification, with yields ranging from 10% (103 nmol,
9-AAF) to 0.05% (0.5 nmol, 120-AAF) from a 1 mM scale
DNA synthesis under conditions optimized to obtain highly
pure oligonucleotides. The identity of each of these oligonuc-
leotides was confirmed by MS analysis (Table 2 and Supple-
mentary Material), thus validating this modified ‘ultra-mild’
DNA synthesis and deprotection protocol (summarized in
Figure 2. Site-specific incorporation of dG-AAF and dG-AF into oligonucleotides. Reaction conditions: (a) DMTr-Cl, pyridine (76%); (b) N-ethyldiisopropylamine,
2-cyanoethoxydiisopropylchloro-phosphoramidite, CH2Cl2 (86%); (c) modified ‘ultra-mild’ DNA synthesis as shown in Table 1; and (d) 1 M NaOH, 0.25 M
b-mercaptoethanol.
A
B
Figure 3. Nucleoside composition analyses of 9-AAF (A) and 9-AF (B). The
oligonucleotides 9-AAF and 9-AF were digested with snake venom phospho-
diesterase and calf intestine phosphatase and the resulting nucleosides were
separated using the HPLC gradient described in Materials and Methods. The
elution times were as follows: dC = 3.4 min, dG = 5.5 min, T = 6.3 min,
dA = 8.2 min, 9-AAF = 16.3 min, 9-AF = 16.7 min, dG-AAF = 24.2 min
and dG-AF = 24.8 min.
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Table 1) as the most straightforward method to achieve the
single site-specific incorporation of dG-AAF into oligonuc-
leotides of any desired length or sequence.
Test of the dG-AAF and dG-AF substrates during an
in vitro NER assay
To demonstrate the usefulness of the dG-AAF- and dG-AF-
modified oligonucleotides, we used them as substrates for
in vitro NER assays. This assay consists in mixing a plasmid
or an oligonucleotide containing a single lesion, with a NER
proficient cell extract. The excision reaction (36–38) results in
the release in solution of short oligonucleotides (24mer to
32mer) containing the lesion, which can be indirectly detected
with an appropriate ‘fill-in’ labeling (see Figure 4 for details).
We wished to use, directly from the DNA synthesizer, the
120mer containing the dG-AAF modification as substrate
for the NER reaction. Although 120-AAF was devised to
meet the size and damage-position requirements to allow
the assembly of the NER machinery (51), we were unable
to detect any significant signal of repair activity after incuba-
tion with HeLa cell extract (data not shown). We do not
presently know whether the 120mer was too short or whether
an unrelated activity in the cell extract such as a non-specific
nuclease or a protein that binds to DNA ends (52–54) preven-
ted the NER reaction from occurring.
We, therefore, turned our focus on incorporating the dG-
AAF and dG-AF adducts into a plasmid to study NER accord-
ing to a well-established protocol (45). The 24-AAF and
24-AF oligonucleotides were incorporated into pBluescriptII
SK+ plasmid using primer extension by T4 DNA polymerase,
ligation with T4 DNA ligase and purification over a caesium
chloride/ethidium bromide density gradient as described by
Shivji et al. (45). We included an additional agarose gel puri-
fication step to remove the excess of 24-AAF (or 24-AF)
primer, which was found to remain associated with the plas-
mid during CsCl gradient purification. Although this extra
purification step was not required for plasmids containing a
cisplatin lesion [(45) and data not shown], it is likely that the
aromatic nature of the dG-AAF (or dG-AF) adducts prevented
the primer from being completely eliminated during the course
of the protocol established by Shivji et al. (45). The plasmid
containing the lesion was then incubated with HeLa whole-cell
extracts and the excised products of the NER reaction were
detected with a ’fill-in’ labeling to yield the NER-specific
pattern of 28mer to 36mer oligonucleotides (Figure 4). We
found that, while a non-damaged mock treated plasmid did not
yield any excised product [(45,55,56) and data not shown], the
plasmid containing dG-AAF was incised at least 20-fold more
efficiently than the one containing dG-AF (Figure 4, compare
lanes 2 and 4). Although it had been demonstrated previously
that dG-AAF adducts are repaired more efficiently then dG-AF
by the human NER machinery (9,57), this surprisingly rep-
resents the first direct comparison of the incision rates of these
two lesions. Our approach allows thus to generate any desired
site-specifically modified dG-AAF or dG-AF plasmids, mak-
ing it possible to address the influence of the sequence context
on the structure, mutagenesis and repair activities of AAF and
AF adducts.
SUMMARY AND CONCLUSIONS
We have reported the development of a modified ‘ultra-mild’
DNA synthesis and deprotection protocol and its application to
the synthesis of oligonucleotides containing dG-AAF residues.
Central to this protocol is the use of a 10% diispropylamine/
0.25 M b-mercaptoethanol methanolic solution that is effect-
ive in removing the protecting groups from oligonucleotides
prepared with the commercially available ‘ultra-mild’ phos-
phoramidites and in releasing them from Q-solid support,
without cleaving the base-labile acetyl group at N8 of dG-
AAF. We have fine-tuned this protocol such that it can be
used for the synthesis of oligonucleotides up to 120 residues
in length without any decrease in coupling yields or depro-
tection efficiency compared with the standard DNA synthesis
conditions. The ability to generate oligonucleotides containing
base-labile mutagenic adducts by solid-phase synthesis is a
significant advance over the synthesis of these adducts by post-
synthetic modification of DNA with carcinogens. It provides
straightforward access to the well-defined substrates for
mutagenesis and DNA repair studies. This protocol is now
routinely used in our laboratory for the preparation of oligo-
nucleotides containing modifications that require special care
during the deprotection step.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
Figure 4. NER dual incision activity on dG-AAF and dG-AF-containing
plasmids. Plasmids containing site-specific dG-AAF or dG-AF residues were
incubated with cell extracts prepared from HeLa cells. The 24mer to 32mer
excision products containing dG-AAF or dG-AF were detected by annealing to
a complementary oligonucleotide with a 50-GpGpGpG overhang, which served
as a template for end-labeling with [a-32P]dCTP with sequenase. The reaction
products were resolved on a 14% denaturing polyacrylamide gel. An MspI
digest of pBR322 was used as a size marker and the position of the 27 and 35 nt
bands are indicated.
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